Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | DRD1 | P21728 | 5/20 | 0.44 |
| ▸ | DRD5 | P21918 | 5/20 | 0.44 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | DRD4 | P21917 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495858 | 0.89 | KDM1A (0.53) | KDM1ASLC6A2SLC6A4SLC6A3DRD2 | |
| SCHEMBL5735496 | 0.88 | KDM1A (0.51) | KDM1ACYP2C19SIGMAR1POLA1 | |
| Hydrochloric Acid SCHEMBL23421993 | 0.86 | KDM1A (0.50) | KDM1ASLC6A2SLC6A4SLC6A3DRD2 | |
| SCHEMBL8438614 | 0.84 | KDM1A (0.49) | KDM1ASLC6A2SLC6A3ADRA2ASIGMAR1 | |
| SCHEMBL31650219 | 0.83 | KDM1A (0.58) | KDM1ACYP2C19DRD2DRD1DRD5 | |
| SCHEMBL8557742 | 0.83 | KDM1A (0.44) | KDM1ASLC6A2SLC6A4SLC6A3CYP2C19 | |
| SCHEMBL23421994 | 0.83 | KDM1A (0.48) | KDM1ASLC6A2SLC6A4SLC6A3DRD2 | |
| SCHEMBL5749365 | 0.83 | KDM1A (0.58) | KDM1ACYP2C19DRD2DRD1DRD5 | |
| SCHEMBL23422132 | 0.81 | ESR1 (0.48) | KDM1ASLC6A2SLC6A4SLC6A3DRD2 | |
| SCHEMBL24676662 | 0.80 | KDM1A (0.48) | KDM1ASLC6A2SLC6A4SLC6A3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-8658806-B2 | Process for preparing optically active antrocin | DEYEW BIOTECH CORP. (TW) | 2014-02-25 | — | — | US | disclosed |
| US-8658806-B2 | Process for preparing optically active antrocin | DEYEW BIOTECH CORP. (TW) | 2014-02-25 | — | — | US | disclosed |
| US-20130096324-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE ANTROCIN | DEYEW BIOTECH CORP. (TW) | 2013-04-18 | — | — | US | disclosed |
| US-20130096324-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE ANTROCIN | DEYEW BIOTECH CORP. (TW) | 2013-04-18 | — | — | US | disclosed |
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096324-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE ANTROCIN | KTN1, TMSB10, TSN | KDM1A 4315/4885SLC6A2 3772/4885SLC6A4 2487/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | KDM1A 2106/4885SLC6A2 1708/4885SLC6A4 1967/4885 |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | CNR1, AVPR1A, OPRL1 | KDM1A 3126/4885SLC6A2 741/4885SLC6A4 870/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KDM1A 2106/4885SLC6A2 1708/4885SLC6A4 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.